Article 02 Oct 2023 FDA Grants Priority Review To Merck's Application For KEYTRUDA (Pembrolizumab) As Part Of Treatment For Early-Stage Cervical Cancer United States Healthcare
Article 02 Oct 2023 Regulatory Update On Alvotech's AVT02, A High-Concentration Interchangeable Adalimumab Biosimilar United States Healthcare